Take your benefits plan, and even if you're somebody during open enrollment right now and you're trying to figure out what's the best plan, take the PDF of your — if you're the employer — of your pharmacy benefit, your consultant contract, your TPA for the claims processing, your RFP, anything that has a contract or a document, put it into your AI and just use the prompt: 'Where are they me over?'
Hey everyone, welcome back to Receipts. I'm Katherine Rampal, the economics editor here at The Bull Work. And I am delighted to be joined by billionaire entrepreneur, former Shark Tank star, and one of the biggest disruptors of the healthcare industry, would you believe it? Mark Cuban. Mark has built a career on transforming businesses. Healthcare obviously is a very different kind of beast and maybe perhaps a more challenging set of business obstacles. So today we're going to talk about who's really making money in the US healthcare system, why Americans pay so much, and whether Mark's company Cost Plus Drugs can actually change the economics of healthcare, maybe even the economics of the US federal budget. Mark, thanks so much. Welcome to the show.
Thanks for having me, Catherine.
So why don't we start with you just explaining to those who are unfamiliar how Cost Plus Drugs works and how you came up with this as a concept.
So how I came up with it: I got a cold email from my now co-founder, Dr. Alex Oshmayansky, and he wanted to manufacture drugs that were on the short supply list. Believe it or not, there's things like pediatric cancer drugs, pitocin, epinephrine that go on short supply and obviously can impact the health and well-being of a lot of people. So he wanted to manufacture those. I'm like, 'Okay, that's interesting, but let me dig into the pharmaceutical business and see what I can learn.' Right around the same time, the pharma bro was going to jail. You started digging in there. You know, he took a drug, Daraprim, and jacked it up, you know, 700.
This is Martin Shkreli for those who are unfamiliar. Pharma bro. Yep.
And I'm like, look, if he can do that, something's wrong with this industry. And as we all know, when you think about buying medications or any healthcare, even if there's some prices posted, people really don't know what they're going to pay, particularly when they get to the pharmacy counter. And so I thought, you know what, this is an opportunity because what's missing on the economic side of healthcare is trust. Nobody trusts the economics of healthcare. And you can't blame them. We've all heard the stories of people showing up at the pharmacy counter and turning away because they couldn't afford it, people who couldn't afford their healthcare, etc. So, I decided to take a different approach. I'm like, 'Okay, we're going to create this website called costplusdrugs.com.'
And what's going to make it different is that when you come to costplusdrugs.com and you put in the name of the medications, if it's one of the thousands we carry, we're going to show you our actual cost, literally what we pay for it. Then, we're going to show you our markup, which is going to be a very fair 15%. And then because we're mail order, we're going to say here's — we pay $5 for the pharmacist to review it and $5 to ship it to you. And all that together, we're going to be a lot cheaper for any of the more expensive generics or brand drugs that we carry. Right? And that was January of 2022. We had 111 generics and it's just exploded since then. And you know, the real product we sell aren't medications. It's trust. And trust in my mind is a formula that we've built the entire business around: trust equals transparency divided by self-interest. Transparency in that we show you our cost. Self-interest, it's only 15%. And that's consistent. We don't change the price no matter who you are, where you are, the time of day, like so many others do. They sell to whatever they can maximize their revenue for. We sell for what's fair to everybody.
That started us and we've since expanded. Now we have that manufacturing and we not only have manufacturing in Dallas where we sell these short supply sterile injectables, but we also have shrunk that using AI and robotics so that it went from a football field size to 5,000 square ft to the size of a tractor trailer, what we call pods, and now we can ship those pods into ecological disaster areas, disasters, military disasters, and the government actually has bought a couple of those from us. So, and then the biggest opportunity for us is we're able to take our manufacturing, whether it's our facility or our pods, and manufacture N-of-one therapies so that if there's somebody that is one of 10 people in the world and they've raised money and we're fortunate enough to find doctors who could find a therapy that helps them in some manner, it's really hard still to get it manufactured. We've been able to take what might be 300, 700, or a million dollars in a month or six months or a year and shrink it down to eventually $50,000 in a couple months. That's basically the pipeline.
Let's dig into that. So, why is it that your company is able to do this and that other companies have not entered this industry? It seems like there should be money lying on the table, right? If in fact it's as simple as you have laid out that all you need to do is manufacture the drugs and undercut your competitors.
Two different businesses here, right? Two different businesses here. So on the direct-to-patients, right, costplusdrugs.com, there's nobody out there who can survive on 15% margins but us. We're not trying because we're lean and mean. We were designed to be lean and mean. Everybody else — I mean, there's individual pharmacies that can do it, but to do it on a national basis, you, you know, put aside the AI, put aside the automation, you have to be willing to not be trying to make as much money as you can. That's the key differentiator. We're not in this business to try to maximize our revenues, or I shouldn't say maximize our profits. If we break even, which — and we're right around break even — if we break even, I'm completely happy. On my interests, our interests as a company are aligned with patients. There aren't many, if any, companies out there that are willing to do that.
On the manufacturing side, others have tried and failed. Many have tried and failed to shrink the manufacturing plant. We, you know, my partner Dr. Oshmayansky, he's one of those guys who graduated college when he was like 13 or something ridiculous. Likes to do math theorems for fun and has been able to truly uniquely do something. The government put out bids to others to try to do it and they've all failed. We've been the first one to be successful at it.
It seems like if there's a business opportunity out there to make any money, somebody should be entering, right? That I guess that's what I'm confused by. Why is it that if you are still profitable, even if you are just like a teeny tiny bit profitable? It seems like there should be others who are entering this space. And I guess I'm wondering what it tells you about — I don't know if it's regulatory barriers or something about the landscape here.
Okay. So, let's talk about the landscape. Of the thousands of drugs we sell, there's only a few that are brands, only a few that are specialty brands. And the reason for that is the big PBMs, the big three PBMs and the vertically integrated companies that own them — you know, the big UnitedHealth, Cigna, CVS, etc. — well, they've gone to the brands and they've said, 'If you work with costplusdrugs.com, we are going to diminish your whole portfolio of brand medications on our formulary, which in turn can cost you tens, hundreds, billions of dollars.' And so, when you ask, you know, why don't others do this? Others have gotten into the medication business trying to be a low-cost providers, but they've worked with the bad guys. We don't work with the bad guys. We work outside the bad guys. We don't have any agreements with the biggest three pharmacy benefit managers and that's because we don't like the way they do business and they're so big they think they can dominate and tell people how to work. Everybody else that I've seen try to get into the space has tried to work inside the system and I just don't think that works.
You also mostly work outside of the insurance system. Is that right? Is that the case that most of the people who come to costplusdrugs.com are doing it without — or are buying from —
Not anymore.
Not anymore. So the insurance industry itself, there's the big guys that they call the BUAs, right? And then there are smaller companies like there's a company called Network Health which sells Medicare Advantage out of Wisconsin and they use us to save their members money on biosimilars, on specialty generics, and they say it's enabled them to keep their premiums and their deductibles for their members down. There are other — we also partner with independent transparent pharmacy benefit managers: Smith RX, Rightway, Judy — there's a whole long list. There's like 30 of them and they work with self-insured companies and offer plans, insurance plans or become part of insurance plans who then when they partner with us can come and get their medications through us that we carry. So, we partner with third parties, but not with the biggest BUAs, the biggest carriers.
So, what does that mean then in terms of who your customer base is? If you're mostly working outside of the insurance system — not entirely, but mostly — is Cost Plus mainly like a stopgap for people with employer plans or who are waiting on public program eligibility? Is it something that insured patients use long-term even though cash — well, I mean like cash purchases don't count towards a deductible, right? So eight —
In eight states they do. In eight states they do, right? Texas, Indiana, and I'm pushing to make that, you know, typical across all states and potentially even federal. So because that's one way to make the market a little bit more efficient. But to answer your question on who our customers are: sure, if you're uninsured or underinsured, then we're a prime opportunity for you to buy medication from us. But typically what happens is people will make a choice. Right now we're in open enrollment and they'll look at the drugs they're currently taking and then they'll say, 'Okay, here's the plan that's best for me because it covers these two drugs I take,' whatever it may be. And then boom, all of a sudden they go to the doctors in March, right? And they realize they need a new drug that might be for MS or it might be for, you know, heart transplant rejection, whatever it may be, and because we have a much better price and their out-of-pocket cost, their coinsurance in particular is particularly high, they'll come to us instead even if it doesn't count against their deductible. And we see that significantly with Medicare Advantage or Medicare Part D plans because if it's not part — you know, because Part D is run by the big conglomerates, right? The United, etc. have Part D plans and the Medicare Advantage plans, the same thing. And so if the plan you choose does not offer the drug you've just been prescribed and it requires coinsurance which might be 20 or 25% of a very inflated price that they've set up, it's cheaper to come to us.
So, is the idea that you're kind of competing with insurance or that you'll be absorbed into insurance? Like, are you expecting to develop partnerships with the bigger plans, the, you know, United Healthcare? And
Absorbed as in acquired? No.
No, but let them use us. Yes. So, we're the only pharmacy that publishes a price list. We're the only pharmacy that has an API where anybody can pull our prices any time of the day. And our prices, as I said, are the same for everybody any time. So, if any of the big insurance companies decide they want to add us as a network to their pharmacy benefit, they can do it. We encourage it. We don't require a contract in most cases. It's just, hey, if Cost Plus Drugs is cheaper, use us. And we say that to self-insured employers as well. You know, the smart ones will look at the negotiations they're having with a pharmacy benefit manager and they'll say, 'Hey, as part of our contract, we always want to use Cost Plus Drugs as a benchmark. If you're cheaper, we'll buy from you. If they're cheaper, buy from them.' And so, we're used there very often as well. So, anybody can include us in any type of plan that they choose. We have no restrictions at all.
A lot of skincare makes big promises, but often underdelivers. But One Skin is different and that's why I've really been looking forward to using their products. They never set out to become a skincare company. Founded by four PhD longevity scientists, they focused on one thing: skin aging. They tested the bestselling anti-aging products on the market and found the same hard truth over and over. Most of them weren't working on the actual cause of aging. They were all just working on the surface signs of aging. And turns out some didn't really work at all. After years of research and testing over 900 novel peptides, they developed OS-1, their proprietary peptide proven to address a leading driver of visible skin aging. It's the foundation of every product they make. So over time, you'll see smoother skin, more even tone and radiance, and visibly fewer fine lines. Skin that both looks and acts younger. I'm really looking forward to trying One Skin. I know that Tim, Sarah, Mona, and others at the Bull Work have raved about their One Skin experience. One Skin's results are backed by four peer-reviewed clinical studies, over 10,000 five-star reviews, and they've been recognized by Bloomberg and Fast Company as a leader in skin longevity. Born from over 10 years of longevity research, One Skin is helping you unlock your healthiest skin now and as you age. For a limited time, try One Skin with 15% off using code receipts at oneskin.co/receipts. That's 15% off oneskin.co with code receipts. After you purchase, they'll ask you where you heard about them. Please support our show and tell them we were the ones who sent you.
It looks like, and I think you mentioned this, almost all of the drugs that you offer are generics. I think generics in the US in general, even not on Cost Plus Drugs, are relatively cheap compared to Europe and elsewhere. It's the branded drugs where there's like a big difference between how much Americans pay versus how much people in other countries pay. Do you think that your model can help with branded drugs and specialty?
Absolutely. So, here's why I mentioned earlier they won't let us work — they won't let the brands work with us. And I'll explain exactly why in two parts. One, they saw what happened with specialty generics. There literally are specialty drugs that are pills, right? It might be for MS, etc. A lot of the different issues I mentioned. And when we started publishing our price list, the price of those specialty generics dropped like a rock because people started realizing they were getting overcharged, particularly self-insured employers that understood what was going on. And there's even a study coming out that's saying all parts of healthcare have seen increases in prices except in 2022 the price of generics started to go down.
And you think that's because of Cost Plus Drugs?
100%. There's no question about it, right? Because we get to see and we get to talk to employers. You know, I was testifying in front of a Senate panel and the guy who runs CalPERS was sitting next to me and said that he used Cost Plus Drugs' price list to negotiate with CVS and said they had to match or beat our pricing. So, I know with 100% certainty that that's the case. But the bigger issue is how the PBMs — and again, when I say PBMs, one of the big mistakes I made when I first got involved with pharmaceutical benefits was that I just looked at PBMs as standalone companies. They're not. They're part of these huge conglomerates. United owns Optum, CVS owns Caremark, right? Cigna owns Express Scripts, you know, and so when you look at them, the culture of these huge organizations, these multi-hundred-billion-dollar revenue companies is the same from top to bottom. You know, United has 3,000 subsidiaries, does $150 billion in intercompany transfers, which makes just their intercompany transfers the 14th largest state by GDP. Right? It's crazy how much and how big these companies are. And the point of that is to demonstrate their power. They have so much power, they're able to influence how drugs, how the drug supply chain works.
Not only can they tell the brand manufacturers not to deal with Cost Plus, but I'm going to give you an even worse example, and this truly distorts and gums up every bit of the drug supply chain and how prices are set for everybody. So when a drug like Xarelto, right, an anticoagulant from J&J, and I'm just using this as an example, when it's sold from J&J to one of the big three distributors — McKesson, Cencora, Cardinal, I know they change their name sometimes, but these companies also do hundreds of billions of dollars in sales — you would think they'd be able to negotiate a great price. Well, the retail price, the list price of Xarelto is $600. When it's sold by J&J to any of those big three distributors, you know what the price they charge them is?
And if they pay promptly and provide some data, they get a whopping 5% discount. So using the Xarelto as an example, the net price that the distributors pay is $570, which means that's the lowest price they can charge any pharmacy.
Now, when you compare that $570 to the net revenue that J&J — and again, this is just an example, it applies to all the brands and all the specialty drugs — it's about 50%. So the net revenue to J&J is about $300. The collected amount is 570. Where's the other 270 go? It goes right to the PBM. Now, the net result of that is that they've got $270 to play with in any way they want. And they'll find a lot of different ways to put that money in their pocket or some portion of that money in their pocket. But here's the worst part, Katherine. The absolute worst. Now that the pharmacies have paid $570, when someone who's uninsured walks in the door, that's the least amount they can charge them. When somebody with a high deductible plan, that's the least amount. When Katherine walks in to buy a brand medication and you're in your deductible phase, unless your employer or whoever you get your insurance from negotiated something specific to that, you're paying $600. And so that is crazy.
And to make matters even worse, because the distributors don't make any money on brands, in order to generate profits, the most profitable part of their business is generics. And those distributors, when they sell to pharmacies, they have something called a generic compliance ratio. And what that means is if you want to buy these brands from us, in order to buy these brands, we are tagging along an inflated price for generics. So you have to pay more for your generics.
Can we just break it down, like what the different steps are for people who are not as familiar with this whole supply chain? So there's the drug maker, who sells to the drug distributor, who sells to the pharmacy and the PBM. The PBM fits where into all of this?
So the PBM is the one who determines what's in your plan, what's on the formulary in your plan.
And because that has so much control and so much leverage — because if the drug you're selling as a brand manufacturer is not on a formulary, let's just say in tier one, right? That first tier with no or low copay, your sales are going to be a whole lot lower. And so in order to make — for the drug maker, right? So in order to maximize their sales, that delta between the $570 that the brand manufacturer receives and the $300 net revenue that they end up with, that $270 is funneled right to the PBMs, right to the pharmacy benefit managers, and they get to do whatever they want with that. Now, there's a lot of legislation saying they have to pass that through to employers or other areas, but they're gaming that system like they game everything. But the two main takeaways are because of this system that the PBMs — and again, vertically integrated with the big carriers, right? Because this is the system that they force on all of us.
Everybody, in the case of an anticoagulant like this, everybody who doesn't have insurance is probably paying twice as much as they otherwise would because if you work the numbers backwards and you go to the brand, right, who receive $300 net, well, if they sold to the distributors at $310, the brand would make $10 more. Now the distributor who sold for 570 to the pharmacist, they just bought for 310. They could sell for 320 to the pharmacist and they made $10. And now the pharmacist who bought for 320, if they're a small independent pharmacist, they're not using as much cash, which really helps their business a lot, and they can sell to any patient for $315 and make more money than they're currently making. And for anybody who's in their deductible phase, they also could price it as part of a plan for $315, $320. And so when we talk about the cost of healthcare in this country and we talk about the middlemen creating the discrepancy for brand drugs but not generic drugs, as you astutely mentioned, right? It is because of these vertically integrated middlemen that are destroying the trust and economics of healthcare in this country.
So the US spends more money per capita on healthcare than any other country. Where are we actually overspending the most? It's not only on drugs, right?
No, but the same thing happens on healthcare as well. Exact same thing. Again, vertically integrated companies, same culture. So these huge conglomerates also have these things called third-party administrators, right? And the third-party administrator, their job is to take a claim for a hip replacement and then have a relationship with a hospital to do the hip replacement and negotiate a price between the third-party administrator and the provider. And because they're part of the plan, that's part of your health plan that now in open enrollment you're choosing between, right? So you choose option A from this carrier, United or whoever, Cigna, right? And the person who has to process all the claims or the company that has to process all the claims is called a third-party administrator and it is owned by the big carrier that's putting together the healthcare plan for you, and they do spread pricing on that hip replacement.
So that the agreement between the third-party administrator and the hospital for that hip replacement might be $25,000. But the way they'll structure it is they'll find ways to make sure that they're charging the employer who's responsible for paying for that plan not the 25,000 that was paid to the hospital, but 27, 28, 30,000, whatever it may be. And it may not be in one flat charge. It may be with a dozen different fees, a dozen different clawbacks. And so when you look at the overall cost of things, it all goes back to those middlemen and how much of our healthcare spend — the 5 whatever trillion dollars now — is attributable to them. Well, how much are their profits? How much are their revenues? You know, how much are they retaining? I mean, and how much administrative cost is created because of that?
I guess what I'm wondering is, is there a way to transpose the model from Cost Plus Drugs onto these other kinds of healthcare services like an appendectomy or a hip replacement surgery or what have you? Because with drugs there's an actual formula where you know how much the different inputs are, right? Like you know how much of this molecule or whatever — I'm clearly not, you know, not a biochemist. Whereas, if we're talking about a surgery, first of all, it's not one-size-fits-all. Every surgery might be a little bit different from every — you know, every hip replacement might be a little bit different. There's a lot the same, but a lot of things that are different. And the input costs are largely human labor. So how do you — if part of the problem with healthcare costs is that everything else is more expensive? It's not just these middlemen, right? It's doctors in the United States do make a lot more money than doctors in other countries.
I would tell you they don't make enough, but yeah.
Yeah. I mean, I'm not saying they should be paid less, but I'm just saying like — did you ever meet Uwe Reinhardt, the Princeton health economist?
I've read the book. Yeah, I've read the book.
Okay. So, he had this line that every dollar of healthcare spending is somebody else's dollar of healthcare income, right? So if you are cutting back how much is getting paid for the hip replacement surgery, some of that money is going to come out of the pocket of the doctor, of the nurse, of the anesthesiologist.
No. Because so much of it goes to the middleman and to the administration at the hospital and to all the other things happening at the provider that the doctor is the one that's getting it. So they talk about going downhill. Not only is it the patient, not only is it the employer, but the doctors and nurses and caregivers are getting it just as badly. So, put them aside. They're not — with what we may say, they're not the ones that are going to lose it or gain it, right? So, what happens? So, whether it's a hip replacement, whether it's something gnarly that happened and you don't know all the pieces, you can still track it, right? The hospital has to know what their costs are. At least they're supposed to know what their costs are. A lot of them truly don't, which is part of the problem. But if — let's just say the question I think is, can you remove the middlemen that are taking advantage of everybody? And the answer is yes, right? So just like there are different types of pharmacy benefit managers — there's the big three and then there's pass-through PBMs who understand they have to be transparent — there are third-party administrators that are part of the big carriers and vertically integrated, and then there are independent third-party administrators.
The independent third-party administrators will just charge you for their services. That's it. And on top of that, they'll let you do direct contracting with those providers. So, for my companies, we switched to an independent third-party administrator called Sage, and we also started doing direct contracts with providers. And I went to them and said, 'Look, I realize that these big insurance companies and their third-party administrators, they are, you know, underpaying you, late paying you, clawing back, taking advantage of time value money, too many pre-authorizations, too many denials, eating up your doctor's time with peer-to-peers to try to overcome that. And then on top of that, because the plans they're offering keep on increasing their premiums and their deductibles, they're turning you, the hospital, into a subprime lender because most people can't afford their deductible or their total out of pocket. And so the hospital or provider will lend them that money and let them pay it over time so they can get access to the insurance company money.' So I said, 'All these things are happening. I understand it. So let's do this, hospital or provider or doctor or whatever. Let's do a direct contract and I will make sure that I trust the doctor. So unless it's something crazy, I'm going to pay you the price we negotiated and I'm not going to have a denial at all and I'm going to take financial responsibility for my members, my employees and their families, their patient out of pocket. Now, in exchange for those things, which makes your life easier and less expensive, I want two things. I want a much better price, and I want the ability to take this contract that we do with each other and post it on an open-source website that we created called costpluswellness.com.'
And by posting it on costpluswellness.com, any other employer can come in and do the exact same thing, and any other provider can post their contracts with pricing and everything. So everybody gets to see what the prices are. So it's more like generic drugs than brand drugs, right? Because it's a lot more transparent. Our cost went down, for instance, right? And their yields went up. So when we talk about how do we reduce cost, it's not just pricing transparency like we talk about all the time. It's also contractual transparency because where a lot of this falls apart is actually with self-insured employers. 67% of people who get insurance through work get it through a self-insured employer. And those self-insured employers are dumb when it comes to these contracts. Dumb. Dumb as a box of rocks. They're working with these companies that I told you are making things worse, not trustworthy, jacking up cost, creating all this administrative friction, right? They're continuing to work with them. And what they don't even realize is the contracts they're signing don't do what they think they do.
So, they'll sign a contract that says on the pharmacy side, the PBM, the pharmacy benefit manager, is going to pass through all the rebates on all drugs except for specialty drugs. And then hidden in the documentation, in the terms and conditions, it says the pharmacy benefit manager gets to determine what is or is not a specialty drug. Meaning, they can push everything to where they make more money. And there's a hundred different examples in every contract. The city of Dallas, their pharmacy benefit manager contract, 1,335 pages. There's no humans on the planet with enough coffee who could ever go through that and catch everything. I call that contractual terrorism.
I would imagine similarly having to negotiate, if you're an employer, having to negotiate with every provider one-off for every single iteration.
That's what the TPA does. The TPA has those relationships with the providers. So that they have — they can turn those into a network. And like with my company, we might only have one person in this city, one person in that city. So you can get a wraparound network. We work with Aetna, you know, and it cost us $18 per member per month, I think. And so we have the ability to use them if we need them in those other cities, but even then it's cheaper for us to have our internal people call up a doctor in that town if it's not an emergency and schedule and work out a cash price. And going back to the employers being dumb, right? So like the city of Dallas, like every major employer I've ever talked to, they're the victims of this contractual terrorism. I tell them, 'Send me a contract. I'll run it through my AI models and I'll tell you where they're —'
you're getting ripped off." And if you follow me on LinkedIn, I post a lot of these examples because I use AI agents to go out there and use open records requests for cities and states and school districts, and I run them through some AI and I show, you know, here's where you're getting ripped off, the good news, the bad news. And for individual employers, private employers, I talk to the CEOs and I tell them the same thing. I'm like, send me your contracts, right? I'll run them through AI or you run them through your own AI. Take your benefits plan and even if you're somebody during open enrollment right now and you're trying to figure out what's the best plan, take the PDF of your, if you're the employer, of your pharmacy benefit, your consultant contract, your TPA for the claims processing, your RFP, anything that has a contract or a document, put it into your AI and just use the prompt: Where are they ripping me over? [laughter] Within a minute it's going to be bam, bam, bam, bam, bam, bam, bam, bam, bam.
And the point of this is there is a reason why these big conglomerates don't post their contracts. There is a reason why when I use the open records acts and ask for these copies they always have to include redactions. They say their pricing is proprietary. It's not. They offer their prices to hundreds of thousands of companies. Millions of people have seen their prices. But it's like Fight Club. Number one rule of Fight Club: you can't talk about Fight Club. You can't talk about these contracts either. And because of that, we don't have an efficient market. When you can't have price and information discovery via the contracts, there's no way for it to be efficient. And when there's that information asymmetry like we're seeing now across the entire health care spectrum on the cost side, the contracting side, that's how they're able to take advantage of it.
Well, so my recollection is that in the first Trump presidency, he did, the president did sign some sort of order. I don't know if it was regulation or >> to requiring price transparency for hospitals. Why did that not work then?
It has helped and then they just expanded it recently to increase the penalties if you don't do it. But what would happen is the tick files, what they call them, those price transparency files, were so, initially they were enormous, 10 gig, 10 gigabytes, a trillion, whatever, they were so big nobody could easily use them on their own. Now they shrunk them and made it for repetitive services, your most often used services, so they're more usable, right? But unless you have the contract associated with that, you don't get the fees and everything else. So they can push down the price of that hip replacement, but they don't tell you about the facilities fee, right? That's like me charging 20 bucks to come to a Mavs game and $500 for every cup when you want to buy a beer or a soda, right? And not just saying my tickets are only $20. So again, these vertically integrated health care conglomerates, they're contractual terrorists. They will do whatever they can to extract revenue and margin in any way they can.
Well, it might be from a subsidiary you didn't even know is a subsidiary of theirs. When I listen to the quarterly earnings conference calls for these companies, which I always do, it's really exciting. The one thing I've never heard is them saying because of this investment, because of this change, we are going to be able to reduce the prices to patients and employers. Never. What they'll say is there's been legislative changes for PBM that are going to affect our PBM business, but we're moving everything to specialty and our specialty drugs business is up 10 to 25%. There's these minimally distributed drugs they call LDD, low distributed drugs I think it stands for. Now they're going out and signing exclusives with them so that they can jack up the margins. There's a study, you know, the state of New Jersey is going through all kinds of, AON did a study showing that the prices that they were paying for biosimilars for Stelara and Humira that cost $365 plus shipping from Cost Plus Drugs, they're paying 10x or more for those drugs. And so, you know, not that that's going to change the tide of all the over the costs for health care benefits in New Jersey, but it just goes to show that they are looking for margin anywhere they can find it, knowing they know the details. They know their costs. They know their margins. You don't. I will guarantee you on the health care side, there is not one employer in the universe in this country, the universe of employers in this country I guess I should say, that is able to reconcile what they paid for that hip replacement all in from the bills that they are sent every week, every month, every...
So, bottom line, it sounds like you think the reason why health care is so much more expensive per capita in this country is about middlemen [clears throat] and not about how much the actual services themselves cost.